Stock Alert: Kinnate (KNTE) Trades 7.38% Higher June 23

Equities Staff  |

Kinnate Biopharma Inc (NASDAQ:KNTE) stock was among today's market movers, ending trading higher 7.38% to $11.50 on June 23.

271,392 shares traded today compared to the 30-day daily average of 208,251 shares.

The company's stock has climbed 39.56% so far in 2022.

Kinnate shares have traded in a range between $7.18 and $26.05 over the past twelve months.

The company is set to release earnings on 2022-08-15.

For technical charts, analysis, and more on Kinnate visit the company profile.

About Kinnate Biopharma Inc

Kinnate is focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers. Kinnate’s mission is to expand the reach of targeted therapeutics by developing products for underserved populations. Kinnate utilizes its deep expertise in structure-based drug discovery, translational research, and patient-driven precision medicine, which it refers to as the Kinnate Discovery Engine, to develop targeted therapies. Based in San Francisco and San Diego, California, the Kinnate team is composed of drug discovery experts supported by a distinguished group of scientific advisors.

To get more information on Kinnate Biopharma Inc and to follow the company's latest updates, you can visit the company's profile page here: Kinnate Biopharma Inc's Profile. For more news on the financial markets be sure to visit Equities News. Also, don't forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Symbol info widget is provided by TradingView based on 15-minute-delayed prices. All other article data is provided by IEX Cloud on 15-minute delayed prices or EOD company info.

Stock price data is provided by IEX Cloud on a 15-minute delayed basis. Chart price data is provided by TradingView on a 15-minute delayed basis.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer


Trending Articles

Investors Must Understand 5G Wireless Growth Wave: Jeff Kagan
'Goldilocks' Stocks Will Define This Decade
What You Need To Know About Bear Markets
Is Your iPhone Already Obsolete?



Market Movers

Sponsored Financial Content